Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Income from Continuing Operations (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Income from Continuing Operations for 16 consecutive years, with 861000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 51.68% to 861000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 10899000.0 through Dec 2025, down 139.01% year-over-year, with the annual reading at 10919000.0 for FY2025, 141.52% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 861000.0 at Anika Therapeutics, up from 3136000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 14679000.0 in Q4 2023, with the low at 10350000.0 in Q1 2023.
  • Average Income from Continuing Operations over 5 years is 596150.0, with a median of 2641000.0 recorded in 2023.
  • Peak annual rise in Income from Continuing Operations hit 462.04% in 2022, while the deepest fall reached 848.21% in 2022.
  • Over 5 years, Income from Continuing Operations stood at 3264000.0 in 2021, then soared by 462.04% to 11817000.0 in 2022, then grew by 24.22% to 14679000.0 in 2023, then crashed by 87.86% to 1782000.0 in 2024, then crashed by 51.68% to 861000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 861000.0, 3136000.0, and 4666000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.